Intactis Bio

Intactis Bio operates at the intersection of biotechnology, neuroscience, and computing hardware. Its stated approach combines lab-grown neural tissue, a brain-machine interface, and silicon processors, with electrical stimulation and feedback used to train neural tissue on computational tasks. The product set spans a rack-mountable Biohybrid Processing Unit, the Biocomputation Alpha early-access service, and the broader biocomputation platform. This gives the company a distinct biohybrid-computing proposition rather than a conventional software-only AI offering or a standalone neural-tissue research platform. Its differentiation is therefore best assessed by its integrated system design and its efforts to make the technology accessible through developer experimentation, cloud compute, and Biostack Alpha. The commercial and technical position remains early: the company was founded in 2024, has a reported team size below ten, and has raised $350,000 in structured funding information. Its progress will depend on demonstrating useful workloads, performance, reliability, and practical economics relative to established silicon-based computing.

Intactis Bio’s recorded trajectory moves from early company formation and support toward product and service development. Founded in 2024, it received an Altitude Lab grant on Aug 26, 2024, followed by a $100,000 pre-seed round led by rpv on Sep 1, 2025. The $250,000 seed round led by Nucleus Fund on Feb 24, 2026 brought the reported total funding to $350,000. Product activity accelerated in 2026: Biocomputation Alpha launched on Mar 26, 2026, Cloud Bio Compute as a service was introduced on Apr 21, 2026, and Biostack Alpha launched on Jul 21, 2026. These are meaningful inflection points from platform development toward developer access, service delivery, and public demonstration. The company’s stated hiring needs—computational neuroscience, iPSC cell culture, and AI/ML engineering—reflect the cross-disciplinary capabilities needed to advance that strategy. The available employee range is one to ten, and the listed team record identifies Daniel Rodriguez as CEO and founder. Funding-round data records three rounds, although the grant amount is unspecified; the reported $350,000 total matches the two priced rounds.